Camurus Starts Dosing in Phase 2b Trial of CAM2056 for Obesity and Overweight

• Camurus initiated dosing in a Phase 2b study of CAM2056 in patients with obesity or overweight following the third quarter of 2026.
• The FDA accepted the resubmitted CAM2029 application for acromegaly, setting a December 18, 2026, target decision date.
• Oczyesa received regulatory clearance for acromegaly in Australia during the quarter; Oczyesa XR gained Canadian clearance following the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camurus AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.